Esperion Therapeutics | ESPR - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 9.39B 4.16B 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Alterity Therapeutics Limited AUD 15.77M 9.56M 2023-06
Amarin USD 131.06M 3.6M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Cipla INR 7.96B 39.9M 2025-09
CSL USD 2.16B 633M 2025-06
Cytokinetics USD 129.84M 7.32M 2026-03
Daiichi Sankyo JPY 542.16B 97.68B 2025-09
Eli Lilly USD 5.28B 1.99B 2026-03
Esperion Therapeutics USD 156.16M 11.69M 2026-03
Geron USD 68.9M 10.54M 2026-03
Grifols EUR 979.78M 334.84M 2024-12
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Heron Therapeutics USD 26.12M 2.53M 2026-03
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
Merck USD 5.33B 9.24B 2026-03
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Moderna USD 1.91B 687M 2026-03
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Pfizer USD 1.7B 561M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 2.96B 15.9B 2026-03
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
United Therapeutics USD 1.28B 277.4M 2026-03
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12